Saturday, 22 June 2024
  
Login

Australia's most trusted
source of pharma news

Saturday, 22 June 2024
Listen to this story 
News

First-in-class drug wins TGA tick

Posted 14 November 2022 AM

Last week the TGA waved through two innovative therapies including a dialysis product that CSL just recently added to its pipeline when it completed its mammoth Vifor Pharma acquisition.

The regulator approved the company's Korsuva, a first-in-class kappa opioid receptor agonist, indicated for the treatment of moderate-to-severe pruritus associated with chronic kidney disease in adult patients on haemodialysis.

To see the whole article, please login


Latest Jobs
Pharma in Focus  Jobs

Marketing & Communications (3)

Sales & Customer Relations (29)

Clinical & Medical, R&D (12)

Regulatory, Pharmacovigilance & QA (7)

Other (20)

MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.